A 28-year-old woman with major depressive disorder is started on fluoxetine 20 mg daily. After 6 weeks, she reports significant nausea, tremor, and agitation despite the low starting dose. Pharmacogenomic testing reveals she is a CYP2D6 poor metabolizer. The PMHNP reviews the results to determine the clinical implications and guide medication adjustment.